What is Lidocaine Aguettant 5%?
Lidocaine Aguettant 5% topical jelly or ointment is used on different parts of the body to cause numbness or loss of feeling for patients having certain medical procedures. It is also used to relieve pain and itching caused by conditions such as sunburn or other minor burns, insect bites or stings, poison ivy, poison oak, poison sumac, minor cuts, or scratches.
Lidocaine Aguettant 5% viscous topical solution is also used to treat sore mouth or throat and also reduce gagging during the taking of X-ray pictures and dental impressions.
Lidocaine Aguettant 5% skin patch is used to relieve pain caused by shingles (postherpetic neuralgia).
Lidocaine Aguettant 5% belongs to the family of medicines called local anesthetics. Lidocaine Aguettant 5% prevents pain by blocking the signals at the nerve endings in the skin. Lidocaine Aguettant 5% does not cause unconsciousness as general anesthetics do when used for surgery.
Lidocaine Aguettant 5% is available only with your doctor's prescription.
Lidocaine Aguettant 5% indications
Lidocaine Aguettant 5% (Lidocaine Aguettant 5% HCl) Injections are indicated for production of local or regioinal anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
How should I use Lidocaine Aguettant 5%?
Use Lidocaine Aguettant 5% aerosol as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Wash your hands well before and after using Lidocaine Aguettant 5% aerosol.
- Shake well before each use.
- If you are using Lidocaine Aguettant 5% aerosol on your face, spray it into your hand. Gently apply. Do not spray Lidocaine Aguettant 5% aerosol directly onto your face.
- For other areas, hold the medicine 4 to 6 inches from the skin and spray onto the affected area. Allow the medicine to slowly dry.
- Do not use large amounts of Lidocaine Aguettant 5% aerosol, especially over blistered or raw areas of your skin.
- Do not bandage or wrap the affected area, unless directed otherwise by your doctor.
- If you miss a dose of Lidocaine Aguettant 5% aerosol, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.
Ask your health care provider any questions you may have about how to use Lidocaine Aguettant 5% aerosol.
Uses of Lidocaine Aguettant 5% in details
How to use Lidocaine Aguettant 5% topical
Lidocaine Aguettant 5% description
Each gram contains Lidocaine 50 mg equivalent to Lidocaine Aguettant 5% 700 mg per 10 cm x 14 cm medicated plaster.
It also contains the following excipients: Self-Adhesive Layer: Glycerol, liquid sorbitol (crystallizing), carmellose sodium, propylene glycol (E1520), urea, heavy kaolin, tartaric acid, gelatin, polyvinyl alcohol, aluminum glycinate, disodium edetate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), polyacrylic acid, sodium polyacrylate, purified water.
Backing Fabric and Release Liner: Polyethylene terephthalate (PET).
Lidocaine Aguettant 5% dosage
Lidocaine Aguettant 5% Dosage
Generic name: Lidocaine Aguettant 5%
Dosage form: Transoral Delivery System
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
When the Lidocaine Aguettant 5%® system is used concomitantly with other products containing Lidocaine Aguettant 5%, the total dose contributed by all formulations must be kept in mind.
Isolate the procedure area with cotton rolls and use suction as appropriate. Dry the tissue with air or gauze. Remove the Lidocaine Aguettant 5%® system from its packaging and peel off the clear protective liner. Immediately apply the Lidocaine Aguettant 5%® system using firm pressure. Allow the patch to remain in place until the desired anesthetic effect is produced but not for longer than 15 minutes. Experience in children is inadequate to recommend a pediatric dose at this time.
More about Lidocaine Aguettant 5% (Lidocaine Aguettant 5%)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Other brands: Nervocaine, UAD Caine, Truxacaine, Lidocaine Aguettant 5% HCl, More (4) »
Professional resources
- Lidocaine Aguettant 5% (FDA)
- Lidocaine Aguettant 5% Hydrochloride (Local) (AHFS Monograph)
Related treatment guides
- Anesthesia
- Arrhythmia
- Burning Mouth Syndrome
- Ventricular Fibrillation
- Ventricular Tachycardia
Lidocaine Aguettant 5% interactions
See also:
What other drugs will affect Lidocaine Aguettant 5%?
Beta-blockers increase the risk of bradycardia and hypotension. Norepinephrine and beta-blockers by reducing hepatic blood flow decrease (increased toxicity), isadrine and glucagon - increase the clearance of Lidocaine Aguettant 5%. Cimetidine increases the plasma concentration of Lidocaine Aguettant 5% Haffkine Bio-Pharmaceutical Corporation (displaces from its association with proteins and slows inactivation in the liver). Barbiturates causing induction of microsomal enzymes stimulate the degradation of Lidocaine Aguettant 5% and reduce its activity. Anticonvulsants (hydantoin derivatives) accelerate the biotransformation in the liver (decreased concentration in the blood), for IV injections it may increases cardiodepressive action of Lidocaine Aguettant 5%. Antiarrhythmics (amiodarone, verapamil, quinidine, aymalin) potentiate cardiac depression. Combination with novocainamide may cause CNS excitement and hallucinations. Lidocaine Aguettant 5% Haffkine Bio-Pharmaceutical Corporation strengthens the inhibitory effect of anesthesia (hexobarbital, thiopental sodium), hypnotics and sedatives on the respiratory center, weakens the cardiac effects of digitoxin, enhances muscle relaxation caused by drugs curare like (possible paralysis of respiratory muscles). MAO inhibitors prolong local anesthesia.
Lidocaine Aguettant 5% side effects
See also:
What are the possible side effects of Lidocaine Aguettant 5%?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Lidocaine Aguettant 5%™ has been evaluated in 10 clinical trials, five in adults and five in pediatric patients.
The five adult clinical trials consisted of a randomized, double-blind, parallel-arm, sham-placebo controlled Phase 3 trial that enrolled 693 patients, two randomized, double-blind, crossover design, sham-placebo controlled Phase 1 trials that enrolled 455 patients, and two open-label studies that enrolled 44 patients. A total of 742 adults received an active treatment with an active treatment that delivered a 0.5 mg dose of Lidocaine Aguettant 5%, while 775 received placebo.
The five pediatric clinical trials consisted of five randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients, ages 3 to 18, received either Lidocaine Aguettant 5%™ or a sham placebo device. A total of 906 pediatric patients received active treatment, while 855 received placebo.
Application Site Reaction
The application site was specifically assessed for four categories of skin site reaction (erythema, edema, pruritus, and petechiae).
In adults, erythema occurred in 67.3% of Lidocaine Aguettant 5%™-treated patients, and in 25.0% of placebo-treated patients. Petechiae occurred in 46.4% of Lidocaine Aguettant 5%™-treated patients, and in 7.0% of placebo-treated patients. Edema occurred in 4.3% of Lidocaine Aguettant 5%™-treated patients, and in 0.8% of placebo-treated patients. Pruritus occurred in 9.4% of Lidocaine Aguettant 5%™-treated patients and in 6.2% of placebo-treated patients.
In pediatric patients, erythema occurred in 53% of Lidocaine Aguettant 5%-treated patients, and in 27% of placebo-treated patients. Petechiae occurred in 44% of Lidocaine Aguettant 5%-treated patients, and in 5% of placebo-treated patients. Edema occurred in 8% of Lidocaine Aguettant 5%-treated patients, and in 3% of placebo-treated patients. Pruritus occurred in 1% of patients in both treatment groups.
Adverse Reactions
Amongst the 742 adult patients receiving active treatment and 775 adult patients receiving sham placebo treatment in the 5 adult studies, the percentage of adult patients with any adverse reactions was 3.9% in the active-treated patients and 4.9% in the sham placebo treated patients.
Most adverse reactions were application-site related (i.e., hypoaesthesia (0% active, 0.5% sham placebo), burning (0.54% active, 0.4% sham placebo), and venipuncture site hemorrhage (0.4% active, 1.7% sham placebo)).
The most common systemic adverse reaction was dizziness, which occurred in 0.9% of active-treated adult patients and in 0.7% of sham placebo treated adult patients. No other systemic adverse events occurred in more than two patients in either treatment group.
Amongst the 906 pediatric patients receiving active treatment and 855 pediatric patients receiving sham placebo treatment, the percentage of pediatric patients with any adverse reactions was approximately 9% in each treatment group.
Most adverse reactions were application-site related (i.e., bruising, burning, pain, contusion, hemorrhage), occurring in 4% of pediatric patients in each treatment group.
The most common systemic adverse reactions were nausea (2%) and vomiting (1%).
Lidocaine Aguettant 5% contraindications
See also:
What is the most important information I should know about Lidocaine Aguettant 5%?
You should not receive this medication if you are allergic to Lidocaine Aguettant 5% or any other type of numbing medicine.
Before you receive Lidocaine Aguettant 5% injection, tell your doctor if you have liver or kidney disease, heart disease, coronary artery disease, circulation problems, or a history of malignant hyperthermia.
To treat irregular heart rhythms, your doctor may prescribe a LidoPen auto-injector. This is a prefilled automatic injection device to be used in an emergency. Keep the device with you at all times.
Your doctor will describe the signs and symptoms to watch for when deciding when it's time to use Lidocaine Aguettant 5% injection at home. Never use the LidoPen auto-injector without first calling your doctor.
With the LidoPen auto-injector you will also receive a CardioBeeper to transmit your heart rate and rhythm to your doctor over a telephone. Read all provided instructions and practice using the CardioBeeper.
Lidocaine Aguettant 5% can cause side effects that may impair your thinking or reactions. Unless absolutely necessary, do not drive after using this medication
Active ingredient matches for Lidocaine Aguettant 5%:
Lidocaine in France.
List of Lidocaine Aguettant 5% substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Lidocaine-Zhaohui Pharm (China) | |
| Lidocainehydrochloride (Netherlands) | |
| Lidocainehydrochloride Braun (Netherlands) | |
| Lidocainehydrochloride Fresenius (Netherlands) | |
| Lidocainehydrochloride IMS (Netherlands) | |
| Lidocainhydrochlorid (Germany) | |
| Lidocainhydrochlorid-Braun (Luxembourg) | |
| Lidocaini hydrochloridum Grindeks (Latvia) | |
| LidocainKreussler (Germany) | |
| Lidocalm (Brazil) | |
| Lidocanna Patch | |
| Lidocard (Finland) | |
| Lidocard B. Braun (Germany) | |
| Lidocard B. Braun 2% (Germany) | |
| Lidocard B.Braun (Germany) | |
| Lidocaton without Vasoconstrictor (Kuwait) | |
| Lidochlor (Russian Federation) | |
| Gel; Local; Lidocaine Hydrochloride 2% (Unique) | |
| Lidocom (Peru) | |
| Lidocord (Brazil) | |
| Lidocorit (Austria) | |
| Injectable; Injection; Lidocaine Hydrochloride 20 mg / ml (Gebro) | |
| Lidocorit 2% (Austria) | |
| LIDOCYN | |
| LIDOCYN GEL 1 tube / 30 GM gel each (Harson Laboratories) | $ 0.65 |
| LIDOCYN INJECTION 1 vial / 2 ML injection each (Harson Laboratories) | $ 0.25 |
| LIDOCYN INJECTION 1 vial / 30 ML injection each (Harson Laboratories) | $ 0.48 |
| LIDOCYN PLUS | |
| LIDOCYN PLUS INJECTION 1 vial / 30 ml injection each (Harson Laboratories) | $ 0.50 |
| Lidodan (Canada) | |
| Ointment; Topical; Lidocaine 5% (Odan) | |
| Jelly; Topical; Lidocaine Hydrochloride 2% (Odan) | |
| Ointment; Topical; Lidocaine Hydrochloride 5% (Odan) | |
| Lidodan Endotracheal Non-Aerosol Spray | |
| Liquid; Topical; Lidocaine Hydrochloride 10 mg / dose | |
| Lidodan Endotracheal Non-aerosol Spray liquid 10 mg (Odan Laboratories Ltd (Canada)) | |
| Lidodent (Poland) | |
| Lidoderm Topical application | |
| Lidodex (Indonesia) | |
| Lidodex / amp 50 mg/1 mL x 2 mL x 5's (Bernofarm) | $ 34.10 |
| Lidofast (Italy) | |
| Lidoged (Egypt) | |
| Lidogel (Bangladesh, Poland, Sri Lanka) | |
| Lidogeyer (Brazil) | |
| Lidoject (Germany, Tunisia, United States) | |
| Lidoject 1 | |
| Lidoject 1% (Germany) | |
| Lidoject 2 | |
| Lidoject 2% (Germany) | |
See 1761 substitutes for Lidocaine Aguettant 5% | |
References
- DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "lidocaine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "lidocaine". http://www.drugbank.ca/drugs/DB00281 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lidocaine Aguettant 5% are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lidocaine Aguettant 5%. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
